Clinical trials for Penile cancer and germ cell tumors

23 currently recruiting clinical trials

Phase 3 Penile cancer and germ cell tumors #NCT05874063 #2022-502426-41-00
Germ cell tumor None Systemic Treatment-Naive Systemic Treatment-Naive Good prognosis Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Penile cancer and germ cell tumors #NCT05529251 #2024-514636-25-00
Germ cell tumor Pure seminoma Locally Advanced None Systemic Treatment-Naive Testis Good prognosis
Surgery Radiotherapy Chemotherapy Radiotherapy
11 recruiting sites
Centre Léon Bérard
Phase 2 Penile cancer and germ cell tumors #NCT01887340
Germ cell tumor Pure seminoma Locally Advanced Metastatic None Systemic Treatment-Naive Surgery Testis Other Good prognosis
Chemotherapy Radiotherapy
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 2 Penile cancer and germ cell tumors #NCT01887340
Germ cell tumor Pure seminoma Localized None Systemic Treatment-Naive Surgery Testis Other
Chemotherapy Radiotherapy
1 recruiting site
Gustave Roussy, Campus du cancer, Grand Paris
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors #NCT03093116 #2024-512606-25-00
Metastatic NTRK-1/2/3 1 2 3 or more Targeted therapy
Systemic Treatment-Naive
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors #NCT03093116 #2024-512606-25-00
Metastatic NTRK-1/2/3 1 2 3 or more Immunotherapy Chemotherapy
Systemic Treatment-Naive Targeted therapy
4 recruiting sites
Turning Point Therapeutics, Inc.
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Locally Advanced Metastatic ROS-1 1
4 recruiting sites
Nuvalent Inc.